The following selected financial data should be read in conjunction with Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and consolidated financial statements and notes thereto contained in Item 8. “Financial Statements and Supplementary Data” of this report.
Merck & Co., Inc. and Subsidiaries
($ in millions except per share amounts)
2019(1)
2018 (2)
2017 (3)
2016 (4)
2015 (5)
Results for Year:
Sales
$
46,840
$
42,294
$
40,122
$
39,807
$
39,498
Cost of sales
14,112
13,509
12,912
14,030
15,043
Selling, general and administrative
10,615
10,102
10,074
10,017
10,508
Research and development
9,872
9,752
10,339
10,261
6,796
Restructuring costs
638
632
776
651
619
Other (income) expense, net
139
(402
)
(500
)
189
1,131
Income before taxes
11,464
8,701
6,521
4,659
5,401
Taxes on income
1,687
2,508
4,103
718
942
Net income
9,777
6,193
2,418
3,941
4,459
Less: Net (loss) income attributable to noncontrolling interests
(66
)
(27
)
24
21
17
Net income attributable to Merck & Co., Inc.
9,843
6,220
2,394
3,920
4,442
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$
3.84
$
2.34
$
0.88
$
1.42
$
1.58
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$
3.81
$
2.32
$
0.87
$
1.41
$
1.56
Cash dividends declared
5,820
5,313
5,177
5,135
5,115
Cash dividends declared per common share
$
2.26
$
1.99
$
1.89
$
1.85
$
1.81
Capital expenditures
3,473
2,615
1,888
1,614
1,283
Depreciation
1,679
1,416
1,455
1,611
1,593
Average common shares outstanding (millions)
2,565
2,664
2,730
2,766
2,816
Average common shares outstanding assuming dilution (millions)
2,580
2,679
2,748
2,787
2,841
Year-End Position:
Working capital
$
5,263
$
3,669
$
6,152
$
13,410
$
10,550
Property, plant and equipment, net
15,053
13,291
12,439
12,026
12,507
Total assets
84,397
82,637
87,872
95,377
101,677
Long-term debt
22,736
19,806
21,353
24,274
23,829
Total equity
26,001
26,882
34,569
40,308
44,767
Year-End Statistics:
Number of stockholders of record
110,023
115,800
121,700
129,500
135,500
Number of employees
71,000
69,000
69,000
68,000
68,000
(1)
Amounts for 2019 include a charge for the acquisition of Peloton Therapeutics, Inc.
(2)
Amounts for 2018 include a charge related to the formation of a collaboration with Eisai Co., Ltd.
(3)
Amounts for 2017 include a provisional net tax charge related to the enactment of U.S. tax legislation and a charge related to the formation of a collaboration with AstraZeneca PLC.
(4)
Amounts for 2016 include a charge related to the settlement of worldwide patent litigation related to Keytruda*.*
(5)
Amounts for 2015 include a net charge related to the settlement of Vioxx shareholder class action litigation, foreign exchange losses related to Venezuela, gains on the dispositions of businesses and other assets, and the favorable benefit of certain tax items.